Michael Bachmann

13.2k total citations · 1 hit paper
315 papers, 10.2k citations indexed

About

Michael Bachmann is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Michael Bachmann has authored 315 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Molecular Biology, 107 papers in Oncology and 105 papers in Immunology. Recurrent topics in Michael Bachmann's work include CAR-T cell therapy research (88 papers), Immunotherapy and Immune Responses (63 papers) and Monoclonal and Polyclonal Antibodies Research (63 papers). Michael Bachmann is often cited by papers focused on CAR-T cell therapy research (88 papers), Immunotherapy and Immune Responses (63 papers) and Monoclonal and Polyclonal Antibodies Research (63 papers). Michael Bachmann collaborates with scholars based in Germany, United States and Hungary. Michael Bachmann's co-authors include Marc Cartellieri, Marc Schmitz, Wernér E.G. Müller, Anja Feldmann, Claudia Arndt, Heinz C. Schröder, Rebekka Wehner, Stefanie Koristka, Martin Bornhäuser and Michel Sadelain and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Michael Bachmann

308 papers receiving 10.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

2012 692 citations Marc Cartellieri, Michael Bachmann et al. profile →

Peers

Countries citing papers authored by Michael Bachmann

Since Specialization

Citations

This map shows the geographic impact of Michael Bachmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bachmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bachmann more than expected).

Fields of papers citing papers by Michael Bachmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bachmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bachmann. The network helps show where Michael Bachmann may publish in the future.

Co-authorship network of co-authors of Michael Bachmann

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bachmann. A scholar is included among the top collaborators of Michael Bachmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bachmann. Michael Bachmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended‐Gate Field‐Effect‐Transistor Biosensors 2025 ·Small Science ·(unknown), Christin Neuber, (unknown), (unknown), Liliana R. Loureiro, (unknown), Anja Feldmann, Michael Bachmann, Larysa Baraban	0
2	RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation 2025 ·npj Precision Oncology ·(unknown), Liliana R. Loureiro, (unknown), (unknown), Nicole Berndt, Anja Hoffmann, (unknown), (unknown), (unknown), Claudia Arndt, Martin Schneider, Claudia R. Ball, Michael Bachmann, Marc Schmitz, Anja Feldmann	0
3	Targeted bismuth-based materials for cancer 2025 ·Dalton Transactions ·Amna Batool, I. Kopp, Manja Kubeil, Michael Bachmann, Philip C. Andrews, Holger Stephan	1
4	Impact of Viscosity on Human Hepatoma Spheroids in Soft Core–Shell Microcapsules 2024 ·Advanced Healthcare Materials ·(unknown), (unknown), (unknown), Sandra Hauser, (unknown), Jens Pietzsch, Michael Bachmann, Larysa Baraban	1
5	Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy 2024 ·Journal for ImmunoTherapy of Cancer ·Christoforos Vaxevanis, Michael Bachmann, Barbara Seliger	10
6	Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells 2023 ·Frontiers in Immunology ·(unknown), Nicola Mitwasi, Martin Ullrich, Manja Kubeil, Magali Toussaint, Winnie Deuther‐Conrad, Christin Neuber, Claudia Arndt, Liliana R. Loureiro, Alexandra Kegler, (unknown), (unknown), Claudia Rössig, Jens Pietzsch, (unknown), Michael Bachmann, Anja Feldmann	9
7	Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies 2023 ·ACS Sensors ·(unknown), (unknown), (unknown), Eduardo Sergio Oliveros Mata, Markus Laube, Anja Feldmann, Alexandra Kegler, (unknown), Ciarán Fowley, Jens Pietzsch, J. Faßbender, Torsten Tonn, Michael Bachmann, Larysa Baraban	29
8	Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers 2023 ·Cancer Immunology Immunotherapy ·(unknown), Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Röder, Claudia Arndt, Anja Feldmann, (unknown), (unknown), (unknown), Torsten Tonn, Michael Bachmann, Winfried S. Wels	5
9	Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma 2022 ·Cancers ·Ioana Plesca, Iva Benešová, (unknown), Ulrich Sommer, Luise Müller, Rebekka Wehner, (unknown), Daniela E. Aust, Gustavo Baretton, Michael Bachmann, Anja Feldmann, Jürgen Weitz, Lena Seifert, Adrian M. Seifert, Marc Schmitz	27
10	HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models 2021 ·Cancers ·(unknown), Susan Richter, Nicole Bechmann, Michael Bachmann, Christian G. Ziegler, Jens Pietzsch, Martin Ullrich	15
11	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells 2021 ·Life ·(unknown), (unknown), (unknown), Jürgen C. Becker, Annette Paschen, Dirk Jäger, Winfried S. Wels, Michael Bachmann, Jessica C. Hassel	10
12	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins 2020 ·International Journal of Molecular Sciences ·Marcus Bauer, Christoforos Vaxevanis, (unknown), Haifa Kathrin Al‐Ali, Nadja Jaekel, Michael Bachmann, Claudia Wickenhauser, Barbara Seliger	20
13	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology 2018 ·Journal of Autoimmunity ·Stefanie Koristka, Alexandra Kegler, Ralf Bergmann, Claudia Arndt, Anja Feldmann, Susann Albert, Marc Cartellieri, Armin Ehninger, Gerhard Ehninger, Jan Moritz Middeke, Martin Bornhäuser, Marc Schmitz, Jens Pietzsch, Katja Akgün, Tjalf Ziemssen, Jörg Steinbach, Michael Bachmann	62
14	Sequential Use of Immunoblots for Characterization of Autoantibody Specificities 2015 ·Methods in molecular biology ·Holger Bartsch, Michael Bachmann	0
15	Induction of anti-Ro60/anti-La by immunisation with spectrin and induction of anti-spectrin by immunisation with Ro60 and 4-hydroxy-2-nonenal-modified Ro60 immunisation. 2013 ·PubMed ·Biji T. Kurien, (unknown), Michael Bachmann, R. Hal Scofield	4
16	Degree of modification of Ro60 by the lipid peroxidation by-product 4-hydroxy-2-nonenal may differentially induce Sjögren syndrome or systemic lupus erythematosus in BALB/c mice 2010 ·Free Radical Biology and Medicine ·Biji T. Kurien, A.J. Porter, (unknown), Saqib Iqbal, Anil D’Souza, Ajay Singh, Sima Asfa, Marc Cartellieri, (unknown), Hiroyuki Matsumoto, Michael Bachmann, Kenneth Hensley, R. Hal Scofield	22
17	Immune tolerance to La Nuclear Antigen in the form of late apoptotic cells. 2002 ·Arthritis & Rheumatism ·(unknown), Kenneth A. Davis, Michael Bachmann, Catherine L. Keech, Tom P. Gordon, James McCluskey, (unknown)	1
18	Regulation of leaf sucrose-phosphate synthase and nitrate reductase by reversible protein phosphorylation 1996 ·Rothamsted Repository (Rothamsted Repository) ·Steven C. Huber, Robert W. McMichael, Michael Bachmann, Joan L. Huber, Jack C. Shannon, (unknown), Matthew J. Paul	5
19	Susceptibility of Primary Human Glial Fibrillary Acidic Protein-Positive Brain Cells to Human Immunodeficiency Virus Infection In Vitro: Anti-HIV Activity of Memantine 1991 ·AIDS Research and Human Retroviruses ·(unknown), (unknown), (unknown), (unknown), (unknown), Heinz C. Schröder, Michael Bachmann, (unknown), Wernér E.G. Müller	25
20	Jerusalem und der Tempel : die geographisch-theologischen Elemente in der lukanischen Sicht des jüdischen Kultzentrums 1980 ·Kohlhammer eBooks ·Michael Bachmann	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact